// App-Quantinova.ai

4509 : Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC).

Researchers

Presenter

  • Nizar M. Tannir

Principal Investigators

  • Aung Naing

  • Jeffrey R. Infante

  • Kyriakos P. Papadopoulos

  • Deborah J.L. Wong

  • Michael Korn

  • Raid Aljumaily

  • Karen A. Autio

  • Shubham Pant

  • Todd Michael Bauer

  • Alexandra Drakaki

  • Naval Guastad Daver

  • Annie Hung

  • Peter Van Vlasselaer

  • Joseph Leveque

  • Martin Oft

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • START, San Antonio, TX

  • David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA

  • Caris Life Sciences, Phoenix, AZ

  • Oklahoma University Medical Center, Oklahoma City, OK

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • University of California, Los Angeles, Los Angeles, CA

  • The University of Texas MD Anderson Cancer Center, Leukemia Department, Houston, TX

  • ARMO BioSciences, Redwood City, CA

  • ARMO BioSciences, Redwood City, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Pembrolizumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT02009449

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved